Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men

Liesbeth Vandenput, Fernand Labrie, Dan Mellström, Charlotte Swanson, Thomas Knutsson, Ralph Peeker, Östen Ljunggren, Eric Orwoll, Anna L. Eriksson, Jan Erik Damber, Claes Ohlsson

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Androgens are important regulators of bone and prostate health in elderly men. The role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in men is unclear. We show that specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Introduction: Androgens are important regulators of bone and prostate health in elderly men. Local synthesis and degradation of androgens are likely to be important parameters of biological action of androgens in androgen-responsive tissues. The aim of this study was to determine the role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in elderly men. Materials and Methods: A subsample of the population-based Swedish part of the MrOS study (n = 631, average age = 75.9 years) was investigated. Bone parameters were measured using DXA. Serum levels of total testosterone (T) and dihydrotestosterone (DHT) were measured by gas chromatography/mass spectroscopy (GC-MS); androstane-3α,17β-diol- 3glucuronide (3G) and androstane-3α,17β-diol-17glucuronide (17G) were measured by liquid chromatography/mass spectroscopy. Prostate volume (n = 159) was measured by transrectal ultrasound. Results: The general pattern is that two of the glucuronidated androgen metabolites, namely 17G and 3G, are stronger positive predictors of BMD than the bioactive androgens (T and DHT). In addition, 17G is a clear positive predictor of prostate volume, explaining 4.5% of the variance in prostate volume, whereas the bioactive androgens do not display any association with prostate volume. Conclusions: Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Future studies should determine if the glucuronidated androgen metabolites also reflect other biological correlates of androgenic activity, including prostate cancer, and if low levels might be a marker of general androgen deficiency in men.

Original languageEnglish (US)
Pages (from-to)220-227
Number of pages8
JournalJournal of Bone and Mineral Research
Volume22
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Androgens
Prostate
Serum
Androstane-3,17-diol
Dihydrotestosterone
Bone and Bones
Mass Spectrometry
Health
Liquid Chromatography
Gas Chromatography
Testosterone
Prostatic Neoplasms

Keywords

  • Androgen metabolites
  • Bone
  • Population studies
  • Prostate
  • Testosterone

ASJC Scopus subject areas

  • Surgery

Cite this

Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., ... Ohlsson, C. (2007). Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Journal of Bone and Mineral Research, 22(2), 220-227. https://doi.org/10.1359/jbmr.061018

Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. / Vandenput, Liesbeth; Labrie, Fernand; Mellström, Dan; Swanson, Charlotte; Knutsson, Thomas; Peeker, Ralph; Ljunggren, Östen; Orwoll, Eric; Eriksson, Anna L.; Damber, Jan Erik; Ohlsson, Claes.

In: Journal of Bone and Mineral Research, Vol. 22, No. 2, 02.2007, p. 220-227.

Research output: Contribution to journalArticle

Vandenput, L, Labrie, F, Mellström, D, Swanson, C, Knutsson, T, Peeker, R, Ljunggren, Ö, Orwoll, E, Eriksson, AL, Damber, JE & Ohlsson, C 2007, 'Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men', Journal of Bone and Mineral Research, vol. 22, no. 2, pp. 220-227. https://doi.org/10.1359/jbmr.061018
Vandenput, Liesbeth ; Labrie, Fernand ; Mellström, Dan ; Swanson, Charlotte ; Knutsson, Thomas ; Peeker, Ralph ; Ljunggren, Östen ; Orwoll, Eric ; Eriksson, Anna L. ; Damber, Jan Erik ; Ohlsson, Claes. / Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. In: Journal of Bone and Mineral Research. 2007 ; Vol. 22, No. 2. pp. 220-227.
@article{5cc2bbce48bf41b098ae0d1cfb207fde,
title = "Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men",
abstract = "Androgens are important regulators of bone and prostate health in elderly men. The role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in men is unclear. We show that specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Introduction: Androgens are important regulators of bone and prostate health in elderly men. Local synthesis and degradation of androgens are likely to be important parameters of biological action of androgens in androgen-responsive tissues. The aim of this study was to determine the role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in elderly men. Materials and Methods: A subsample of the population-based Swedish part of the MrOS study (n = 631, average age = 75.9 years) was investigated. Bone parameters were measured using DXA. Serum levels of total testosterone (T) and dihydrotestosterone (DHT) were measured by gas chromatography/mass spectroscopy (GC-MS); androstane-3α,17β-diol- 3glucuronide (3G) and androstane-3α,17β-diol-17glucuronide (17G) were measured by liquid chromatography/mass spectroscopy. Prostate volume (n = 159) was measured by transrectal ultrasound. Results: The general pattern is that two of the glucuronidated androgen metabolites, namely 17G and 3G, are stronger positive predictors of BMD than the bioactive androgens (T and DHT). In addition, 17G is a clear positive predictor of prostate volume, explaining 4.5{\%} of the variance in prostate volume, whereas the bioactive androgens do not display any association with prostate volume. Conclusions: Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Future studies should determine if the glucuronidated androgen metabolites also reflect other biological correlates of androgenic activity, including prostate cancer, and if low levels might be a marker of general androgen deficiency in men.",
keywords = "Androgen metabolites, Bone, Population studies, Prostate, Testosterone",
author = "Liesbeth Vandenput and Fernand Labrie and Dan Mellstr{\"o}m and Charlotte Swanson and Thomas Knutsson and Ralph Peeker and {\"O}sten Ljunggren and Eric Orwoll and Eriksson, {Anna L.} and Damber, {Jan Erik} and Claes Ohlsson",
year = "2007",
month = "2",
doi = "10.1359/jbmr.061018",
language = "English (US)",
volume = "22",
pages = "220--227",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men

AU - Vandenput, Liesbeth

AU - Labrie, Fernand

AU - Mellström, Dan

AU - Swanson, Charlotte

AU - Knutsson, Thomas

AU - Peeker, Ralph

AU - Ljunggren, Östen

AU - Orwoll, Eric

AU - Eriksson, Anna L.

AU - Damber, Jan Erik

AU - Ohlsson, Claes

PY - 2007/2

Y1 - 2007/2

N2 - Androgens are important regulators of bone and prostate health in elderly men. The role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in men is unclear. We show that specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Introduction: Androgens are important regulators of bone and prostate health in elderly men. Local synthesis and degradation of androgens are likely to be important parameters of biological action of androgens in androgen-responsive tissues. The aim of this study was to determine the role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in elderly men. Materials and Methods: A subsample of the population-based Swedish part of the MrOS study (n = 631, average age = 75.9 years) was investigated. Bone parameters were measured using DXA. Serum levels of total testosterone (T) and dihydrotestosterone (DHT) were measured by gas chromatography/mass spectroscopy (GC-MS); androstane-3α,17β-diol- 3glucuronide (3G) and androstane-3α,17β-diol-17glucuronide (17G) were measured by liquid chromatography/mass spectroscopy. Prostate volume (n = 159) was measured by transrectal ultrasound. Results: The general pattern is that two of the glucuronidated androgen metabolites, namely 17G and 3G, are stronger positive predictors of BMD than the bioactive androgens (T and DHT). In addition, 17G is a clear positive predictor of prostate volume, explaining 4.5% of the variance in prostate volume, whereas the bioactive androgens do not display any association with prostate volume. Conclusions: Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Future studies should determine if the glucuronidated androgen metabolites also reflect other biological correlates of androgenic activity, including prostate cancer, and if low levels might be a marker of general androgen deficiency in men.

AB - Androgens are important regulators of bone and prostate health in elderly men. The role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in men is unclear. We show that specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Introduction: Androgens are important regulators of bone and prostate health in elderly men. Local synthesis and degradation of androgens are likely to be important parameters of biological action of androgens in androgen-responsive tissues. The aim of this study was to determine the role of serum levels of glucuronidated androgen metabolites as predictors of BMD and prostate volume in elderly men. Materials and Methods: A subsample of the population-based Swedish part of the MrOS study (n = 631, average age = 75.9 years) was investigated. Bone parameters were measured using DXA. Serum levels of total testosterone (T) and dihydrotestosterone (DHT) were measured by gas chromatography/mass spectroscopy (GC-MS); androstane-3α,17β-diol- 3glucuronide (3G) and androstane-3α,17β-diol-17glucuronide (17G) were measured by liquid chromatography/mass spectroscopy. Prostate volume (n = 159) was measured by transrectal ultrasound. Results: The general pattern is that two of the glucuronidated androgen metabolites, namely 17G and 3G, are stronger positive predictors of BMD than the bioactive androgens (T and DHT). In addition, 17G is a clear positive predictor of prostate volume, explaining 4.5% of the variance in prostate volume, whereas the bioactive androgens do not display any association with prostate volume. Conclusions: Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Future studies should determine if the glucuronidated androgen metabolites also reflect other biological correlates of androgenic activity, including prostate cancer, and if low levels might be a marker of general androgen deficiency in men.

KW - Androgen metabolites

KW - Bone

KW - Population studies

KW - Prostate

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=33846470451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846470451&partnerID=8YFLogxK

U2 - 10.1359/jbmr.061018

DO - 10.1359/jbmr.061018

M3 - Article

C2 - 17059374

AN - SCOPUS:33846470451

VL - 22

SP - 220

EP - 227

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 2

ER -